跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
PMS-DAPAGLIFLOZIN - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
PMS-DAPAGLIFLOZIN
Authorized
STANDARD
PMS-DAPAGLIFLOZIN
Pharmascience Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
e8144c65a93223f6
Company
Pharmascience Inc
Type
Standard
Approval Details
Approval Id
e8144c65a93223f6
Drug Approval Canada Name
PMS-DAPAGLIFLOZIN
Product Name
PMS-DAPAGLIFLOZIN
Status
Marketed
Status Date
2023-05-15
Original Market Date
2023-05-15
Din
02531550
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
68:20.18
Atc Original
A10BK01 DAPAGLIFLOZIN
Atc Name
a 10 bk 01
Aig Number
0156370001
Company Name
Pharmascience Inc
Company Address
100, 6111 Royalmount Ave, Montreal, Quebec, Canada, H4P 2T4
Company Detail Path
/organization/pharmascience-inc
Company Information
Pharmaceutical Company Name
Pharmascience Inc
Country Name
Canada
Province Name
Quebec
City Name
montréal,quebec,country_ca
Address
6111 av Royalmount bureau 100
Active Ingredients
DAPAGLIFLOZIN
5 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
e8144c65a93223f6
Type
Standard
Back to Health Canada Approvals